Excel · study · 2026
Spatial proteogenomics reveals S100-RAGE axis as a druggable mediator of trastuzumab deruxtecan resistance in metastatic breast cancer.
Listed in NCBI GEO
Trastuzumab deruxtecan (T-DXd) has substantially improved outcomes for HER2-positive metastatic breast cancer, yet up to 30 percent of patients with high HER2 expression exhibit de novo resistance.
Description
Mechanisms underlying this intrinsic resistance, particularly across different metastatic sites, remain poorly understood.
Links
Get the data
- GEO FTP directory ftp.ncbi.nlm.nih.gov/geo/series/GSE327nnn/GSE327983 ↗
download · from NCBI GEO
Where it is published
- GEO accession page ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE327983 ↗
landing page · from NCBI GEO
Documentation and papers
- PRJNA1453451 ncbi.nlm.nih.gov/bioproject/PRJNA1453451 ↗
project · from NCBI GEO
- PubMed 42467226 pubmed.ncbi.nlm.nih.gov/42467226 ↗
publication · from NCBI GEO
Topics
- Stated by source
- Homo sapiens · Other
- From keywords
- Life Sciences
- Inferred from text
- Cancer 75%
Provenance · 1 source records, 8 field assertions
| Source | Key | Last seen | Raw |
|---|---|---|---|
| NCBI GEO | GSE327983 | 14 d ago | JSON v1 |
| Field | Assertion | Extractor | Evidence |
|---|---|---|---|
| access_level | source · NCBI GEO | connector:ncbi_geo@1.0.0 | |
| concepts[disease].local:disease:cancer | enrichment · NCBI GEO | keyword-concept-rules@1.0.0 | title+description (75%) |
| concepts[field].local:field:life-sciences | mapping · NCBI GEO | connector:ncbi_geo@1.0.0 | |
| concepts[method].geo_series_type:other | source · NCBI GEO | connector:ncbi_geo@1.0.0 | /gdstype |
| concepts[organism].NCBITaxon:9606 | source · NCBI GEO | connector:ncbi_geo@1.0.0 | /taxon |
| description | source · NCBI GEO | connector:ncbi_geo@1.0.0 | /summary |
| publication_date | source · NCBI GEO | connector:ncbi_geo@1.0.0 | |
| title | source · NCBI GEO | connector:ncbi_geo@1.0.0 | /title |